MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Allergan profits shrink despite 10 percent revenue bump
Allergan Inc. (NYSE:AGN) posted profits of $158.3 million, or 51 cents per diluted share, on sales of $1.27 billion during the three months ended March 31. That compares with profits of $167.9 million, or 55 cents per diluted share, on sales of $1.15 billion during the same period last year.
Read more
Volcano Corp. puffs out of the red
Volcano Corp. (NSDQ:VOLC) posted net earnings of $1.2 million, or 2 cents per diluted share, on revenue of $81.0 million during the three months ended March 31. That compares with losses of $4.0 million, or 8 cents per diluted share, on revenue of $66.6 million during the same period last year.
Read more
NxStage boasts record Q1 sales
NxStage Medical Inc. (NSDQ:NXTM) reported losses of $6.0 million, or 11 cents per diluted share, on sales of $50.6 during the three months ended March 31. That compares with net earnings of $9.0 million, or 19 cents per diluted share, on sales of $40.4 million during the same period last year.
Read more
BioClinica clings to profitability
BioClinica Inc. (NSDQ:BIOC) reported a profit of $351,000, or 2 cents per diluted share, on revenue of $19.7 million during the three months ended March 31. That compares with a profits of $711,000, or 5 cents per diluted share, on revenue of $18.1 million during the same period last year.
Read more
Anika Therapeutics income halves
Anika Therapeutics Inc. (NSDQ:ANIK) posted profit of $324,412, or 3 cents per diluted share, on sales of $11.7 million during the three months ended March 31. That compares with profits of $714,280, or 6 cents per diluted share, on sales of $12.5 million during the same period last year.
Read more
Orthovita losses remain unchanged, but sales dip
Orthovita Inc. (NSDQ:VITA) posted losses of $1.2 million, or 2 cents per diluted share, on revenue of $23.8 million during the three months ended March 31. That compares a loss of $1.2 million, or 2 cents per diluted share, on revenue of $24.1 million during the same period last year.
Read more
Cardiovascular Systems cuts losses after sales jump 22 percent
Cardiovascular Systems Inc. (NSDQ:CSII) reported a loss of $2.4 million, or 15 cents per diluted share, on sales of $20.2 million during the three months ended March 31. That compares with a loss of $6.5 million, or 44 cents per diluted share, on sales of $16.5 million during the same period last year.
Cardiogenesis losses widen as sales dip
Cardiogenesis Corp. (OTC:CGCP) posted a loss of $433,000, or 1 cent per diluted share, on sales of $3.1 million during the three months ended March 31. That compares with a loss of $18,000, or 0 cents per diluted share, on sales of $3.2 million during the same period last year.
Read more
AtriCure losses ease on improved sales
AtriCure Inc. (NYSE:ATRC) posted a loss of $1.3 million, or 8 cents per diluted share, on revenue of $15.6 million during the three months ended March 31. That compares with losses of $2.0 million, or 13 cents per diluted share, on revenue of $14.0 million during the same period last year.
Read more
Fresenius profits rise on increased sales
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported profits of $249.1 million, or 73 cents per share, on revenue of $3.04 billion during the three months ended March 31. That compares with profits of $230.2 million, or 70 cents per share, on revenue of $2.88 billion during the same period last year.
Read more
Dehaier profits halve despite revenue increase
Dehaier Medical Systems Ltd. (NSDQ:DHRM) posted profits of $209,744, or 4 cents per diluted share, on sales of $3.0 million during the three months ended March 31. That compares with a profit of $533,972, or 17 cents per diluted share, on sales of $2.6 million during the same period last year.
Read more
Artimplant losses ease as sales rise
Artimplant AB (STO:ARTIB) reported losses of SEK 3.9 million, or SEK 0.03 per diluted share, on revenue of SEK 5.4 million during the three months ended March 31. That compares with losses of SEK 4.7 million, or SEK 0.08 per diluted share, on revenue of SEK 4.8 million during the same period last year.
Read more
